Skip to main content
PGEN
NASDAQ Life Sciences

Precigen Reports Strong Q1 2026 Results, $21.6M PAPZIMEOS Revenue, Projects Cash Flow Break-Even by Year-End

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.14
Mkt Cap
$1.469B
52W Low
$1.26
52W High
$5.465
52W Position info
229% above low
Off High info
24% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

PGEN has more than doubled off its 52-week low of $1.26.

Summary

Precigen announced strong Q1 2026 financial results with $21.6 million in PAPZIMEOS product revenue and a significantly reduced net loss, projecting cash flow break-even by year-end 2026.


Key Events · Earnings and Guidance · PGEN

  • Strong Q1 2026 Financial Performance

    Reported $21.6 million in net product revenue from PAPZIMEOS in its first full quarter of commercial launch, contributing to a total revenue of $23.252 million.

  • Significant Reduction in Net Loss

    Net loss dramatically decreased to $7.9 million ($0.02 per share) in Q1 2026, compared to $54.2 million ($0.18 per share) in Q1 2025.

  • Projected Cash Flow Break-Even

    The company anticipates funding its operations to cash flow break-even by the end of 2026, supported by current cash and expected PAPZIMEOS sales.

  • PAPZIMEOS Commercial Momentum

    The PAPZIMEOS launch shows strong traction with approximately 400 patients enrolled in the patient hub, broad payer coverage (over 90% of insured US lives), and the implementation of a permanent J-code effective April 1, 2026, streamlining reimbursement.


Analysis · PGEN · Life Sciences

Precigen reported significantly improved first-quarter 2026 financial results, driven by the successful commercial launch of PAPZIMEOS, its first FDA-approved product. The substantial reduction in net loss and the projection to reach cash flow break-even by the end of 2026 are critical for the company's financial stability and future operations, especially following a large net loss in 2025.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PGEN was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.26 to $5.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PGEN - Latest Insights

PGEN
Nov 04, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.99
Real-time Price: $4.63 info
Change: -$0.3573 (-7%) info
Market Cap: $1.621B info
PGEN
Nov 04, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
8
Price at Filing: $5.01
Real-time Price: $4.63 info
Change: -$0.3813 (-8%) info
Market Cap: $1.621B info
PGEN
Sep 21, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.93
Real-time Price: $4.63 info
Change: -$3.30 (-42%) info
Market Cap: $1.621B info
PGEN
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.27
Real-time Price: $4.63 info
Change: -$2.64 (-36%) info
Market Cap: $1.621B info
PGEN
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.35
Real-time Price: $4.63 info
Change: -$2.72 (-37%) info
Market Cap: $1.621B info